169 related articles for article (PubMed ID: 15827185)
1. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.
Wei BL; Denton PW; O'Neill E; Luo T; Foster JL; Garcia JV
J Virol; 2005 May; 79(9):5705-12. PubMed ID: 15827185
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus.
Fredericksen BL; Wei BL; Yao J; Luo T; Garcia JV
J Virol; 2002 Nov; 76(22):11440-6. PubMed ID: 12388705
[TBL] [Abstract][Full Text] [Related]
3. Evidence against a direct antiviral activity of the proteasome during the early steps of HIV-1 replication.
Dueck M; Guatelli J
Virology; 2007 Apr; 361(1):1-8. PubMed ID: 17316734
[TBL] [Abstract][Full Text] [Related]
4. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems.
Luo T; Douglas JL; Livingston RL; Garcia JV
Virology; 1998 Feb; 241(2):224-33. PubMed ID: 9499797
[TBL] [Abstract][Full Text] [Related]
5. Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism.
Qi M; Aiken C
J Virol; 2007 Feb; 81(3):1534-6. PubMed ID: 17108041
[TBL] [Abstract][Full Text] [Related]
6. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor.
Kinomoto M; Yokoyama M; Sato H; Kojima A; Kurata T; Ikuta K; Sata T; Tokunaga K
J Virol; 2005 May; 79(10):5996-6004. PubMed ID: 15857986
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin Gene-Related Peptide Induces HIV-1 Proteasomal Degradation in Mucosal Langerhans Cells.
Bomsel M; Ganor Y
J Virol; 2017 Dec; 91(23):. PubMed ID: 28904199
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.
Chazal N; Singer G; Aiken C; Hammarskjöld ML; Rekosh D
J Virol; 2001 Apr; 75(8):4014-8. PubMed ID: 11264394
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
10. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
[TBL] [Abstract][Full Text] [Related]
11. Infection of baboons with simian/human immunodeficiency viruses.
Allan JS; Ray P; Broussard S; Whitehead E; Hubbard G; Butler T; Brasky K; Luciw P; Cheng-Mayer C; Levy JA
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug; 9(5):429-41. PubMed ID: 7627620
[TBL] [Abstract][Full Text] [Related]
12. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA.
Mautino MR; Morgan RA
Hum Gene Ther; 2002 Jun; 13(9):1027-37. PubMed ID: 12067436
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
14. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
Platt EJ; Kuhmann SE; Rose PP; Kabat D
J Virol; 2001 Dec; 75(24):12266-78. PubMed ID: 11711617
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factor.
Chen J; Dang Q; Unutmaz D; Pathak VK; Maldarelli F; Powell D; Hu WS
J Virol; 2005 Apr; 79(7):4140-9. PubMed ID: 15767415
[TBL] [Abstract][Full Text] [Related]
16. Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity.
Miller MD; Warmerdam MT; Ferrell SS; Benitez R; Greene WC
Virology; 1997 Aug; 234(2):215-25. PubMed ID: 9268152
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.
Nagashima KA; Thompson DA; Rosenfield SI; Maddon PJ; Dragic T; Olson WC
J Infect Dis; 2001 Apr; 183(7):1121-5. PubMed ID: 11237840
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of HIV-1 Nef mutants in the context of viral infection.
Fackler OT; Moris A; Tibroni N; Giese SI; Glass B; Schwartz O; Kräusslich HG
Virology; 2006 Aug; 351(2):322-39. PubMed ID: 16684552
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.
Pugach P; Marozsan AJ; Ketas TJ; Landes EL; Moore JP; Kuhmann SE
Virology; 2007 Apr; 361(1):212-28. PubMed ID: 17166540
[TBL] [Abstract][Full Text] [Related]
20. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
